Abstract
The management of rheumatoid arthritis has changed considerably during the past 15 years. Current strategies emphasize the need for early diagnosis and therapeutic intervention based on the use of disease-modifying antirheumatic drugs. The advent of agents that are more tailored to inhibit the specific disease processes will profoundly affect management. Immunogenetic studies may eventually assist in identifying subgroups of patients with rheumatoid arthritis who have more aggressive disease and who require a more aggressive treatment approach.
Original language | English (US) |
---|---|
Pages (from-to) | 69-74 |
Number of pages | 6 |
Journal | Mayo Clinic proceedings |
Volume | 75 |
Issue number | 1 |
DOIs | |
State | Published - 2000 |
ASJC Scopus subject areas
- General Medicine